These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35714161)

  • 1. Risk factors for Fontan-associated hepatocellular carcinoma.
    Kogiso T; Sagawa T; Taniai M; Shimada E; Inai K; Shinohara T; Tokushige K
    PLoS One; 2022; 17(6):e0270230. PubMed ID: 35714161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of hepatocellular carcinoma arising from Fontan-associated liver disease.
    Sagawa T; Kogiso T; Sugiyama H; Hashimoto E; Yamamoto M; Tokushige K
    Hepatol Res; 2020 Jul; 50(7):853-862. PubMed ID: 32219953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive biomarkers of Fontan-associated liver disease.
    Emamaullee J; Khan S; Weaver C; Goldbeck C; Yanni G; Kohli R; Genyk Y; Zhou S; Shillingford N; Sullivan PM; Takao C; Detterich J; Kantor PF; Cleveland JD; Herrington C; Ram Kumar S; Starnes V; Badran S; Patel ND
    JHEP Rep; 2021 Dec; 3(6):100362. PubMed ID: 34693238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Cirrhosis and/or Hepatocellular Carcinoma Occurring Late After the Fontan Procedure　- A Nationwide Survey in Japan.
    Kuwabara M; Niwa K; Toyoda T; Shirai T; Tateno S; Ohuchi H; Tanaka Y; Ichida F; Fujisawa T; Akagi T; Mori Y;
    Circ J; 2018 Mar; 82(4):1155-1160. PubMed ID: 29445059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery.
    Sakamori R; Yamada R; Tahata Y; Kodama T; Hikita H; Tatsumi T; Yamada T; Takehara T
    J Gastroenterol; 2022 Feb; 57(2):111-119. PubMed ID: 35064829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Outcomes and Prognostic Factors of Acute Variceal Bleeding in Patients with Hepatocellular Carcinoma.
    Lee YR; Park SY; Tak WY
    Gut Liver; 2020 Jul; 14(4):500-508. PubMed ID: 31816673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fontan Hepatopathy-Managing Unknowns.
    Zentner D; Phan K; Gorelik A; Keung C; Grigg L; Sood S; Gibson R; Nicoll AJ
    Heart Lung Circ; 2023 Apr; 32(4):535-543. PubMed ID: 36642589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fontan-associated liver disease and hepatocellular carcinoma in adults.
    Kogiso T; Tokushige K
    Sci Rep; 2020 Dec; 10(1):21742. PubMed ID: 33303924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery.
    Assenza GE; Graham DA; Landzberg MJ; Valente AM; Singh MN; Bashir A; Fernandes S; Mortele KJ; Ukomadu C; Volpe M; Wu F
    Heart; 2013 Apr; 99(7):491-6. PubMed ID: 23406689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort.
    Téllez L; Rodríguez de Santiago E; Minguez B; Payance A; Clemente A; Baiges A; Morales-Arraez D; La Mura V; Llop E; Garrido E; Garrido-Lestache E; Tasayco S; Bruno O; Prieto R; Montserrat S; Pons M; Olavarría A; Dos L; Legendre A; Jesús Del Cerro M; Bañares R; García-Pagán JC; Rautou PE; Albillos A;
    J Hepatol; 2020 Apr; 72(4):702-710. PubMed ID: 31726116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Guerrini GP; Pinelli D; Marini E; Corno V; Guizzetti M; Zambelli M; Aluffi A; Lincini L; Fagiuoli S; Lucianetti A; Colledan M
    Prog Transplant; 2018 Mar; 28(1):63-69. PubMed ID: 29251164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of liver cirrhosis and hepatocellular carcinoma among perioperative survivors of the Fontan operation.
    Inuzuka R; Nii M; Inai K; Shimada E; Shinohara T; Kogiso T; Ono H; Otsuki SI; Kurita Y; Takeda A; Hirono K; Takei K; Yasukohchi S; Yoshikawa T; Furutani Y; Shinozaki T; Matsuyama Y; Senzaki H; Tokushige K; Nakanishi T
    Heart; 2023 Jan; 109(4):276-282. PubMed ID: 35768191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fontan-associated liver disease: A review.
    Gordon-Walker TT; Bove K; Veldtman G
    J Cardiol; 2019 Sep; 74(3):223-232. PubMed ID: 30928109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretransplantation and Post-Transplantation Liver Disease Assessment in Adolescents Undergoing Isolated Heart Transplantation for Fontan Failure.
    Rodriguez DS; Mao C; Mahle WT; Kanter KR; Alazraki A; Braithwaite K; Rytting H; Caltharp S; Magliocca JF; Romero R
    J Pediatr; 2021 Feb; 229():78-85.e2. PubMed ID: 32976893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score.
    Hsu KY; Chau GY; Lui WY; Tsay SH; King KL; Wu CW
    World J Surg; 2009 Nov; 33(11):2412-9. PubMed ID: 19756859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease.
    Suzuki H; Niizeki T; Shirono T; Koteda Y; Kinjyo Y; Mizukami N; Koda M; Ota S; Nakano M; Okamura S; Iwamoto H; Shimose S; Noda Y; Kamachi N; Kajiwara A; Suda K; Akiba J; Yano H; Kuromatsu R; Koga H; Torimura T
    Intern Med; 2022 Apr; 61(8):1145-1150. PubMed ID: 34565776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices.
    Amitrano L; Guardascione MA; Bennato R; Manguso F; Balzano A
    J Hepatol; 2005 Jun; 42(6):820-5. PubMed ID: 15885352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
    Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma and the Fontan circulation: Clinical presentation and outcomes.
    Possner M; Gordon-Walker T; Egbe AC; Poterucha JT; Warnes CA; Connolly HM; Ginde S; Clift P; Kogon B; Book WM; Walker N; Wagenaar LJ; Moe T; Oechslin E; Kay WA; Norris M; Dillman JR; Trout AT; Anwar N; Hoskoppal A; Broering DC; Bzeizi K; Veldtman G
    Int J Cardiol; 2021 Jan; 322():142-148. PubMed ID: 32828959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.